Back to News
Market Impact: 0.35
IDEXX Laboratories Boost FY26 Outlook
Source: Nasdaq
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany FundamentalsM&A & Restructuring
IDEXX Laboratories raised its full-year 2026 earnings and revenue guidance while reporting third-quarter results. The company attributed the higher outlook to acquisition impacts and strong recurring revenue performance at CAG Diagnostics; the article excerpt provides no revised guidance figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
IDXX0.65
More News
- Stocks making the biggest moves midday: Oracle, SpaceX, Tempus AI, Rivian & more
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit
- Choosing an AI Copilot for Equity Research